![Therapix biosciences ltd.](/api/images/company-pic/0-2212432-company.jpg)
Kontaktiere uns
Über das Unternehmen
We are a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, we have initiated two internal drug development programs based on repurposing a U.S. Food and Drug Administration, or FDA, approved synthetic cannabinoid (dronabinol): Joint Pharma develops THX-TS01 targeted to the treatment of Tourette Syndrome, or TS, and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments, or MCIs.
IL
Unbekannt
Nicht verifiziertes Unternehmen
Geschäftstransparenz
- Firmeninfo nicht verifiziert
- Bitten Sie ihre Kunden um Bewertungen
- Auf negative Bewertungen wurde nicht geantwortet